HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin Vapor Ad Claims Review Douses FDA's Dietary Supplement Definition

This article was originally published in The Rose Sheet

Executive Summary

The first review of ad claims for a vitamin vapor device by a Council of Better Business Bureaus investigative unit comes as marketing of the products is proliferating and with FDA stating that "a vitamin product for inhalation cannot be legally marketed as a dietary supplement" in the US.

You may also be interested in...

Sparq's Vitamin Vapor Inhalation Product Could Spark Regulatory Interest

Vitamin Air is so novel, it could get FDA's attention for misbranding as a supplement and being an unapproved new drug. Sparq says it's not an electronic cigarette because there's no nicotine in formulations it offers in products that resemble early-edition e-cigarettes. But it is a dietary supplement because each one is a mixture of vitamins, minerals and supplements plus natural flavors and glycerin so the formulations heat into vapor that is inhaled, the firm says.

FDA Helps E-Cigarettes Navigate NDA Process With Nonclinical Tests Guidance

Commissioner Gottlieb highlights the first of two draft guidances US FDA will publish on developing "novel, inhaled nicotine replacement therapies that could be submitted to the FDA for approval as new drugs, similar to current" OTC  nicotine replacement therapies. FDA has had a contentious history with manufacturers of electronic nicotine devices, but officials have said the products are eligible for review as NRTs through the NDA process.

Another Advertising Review For Goli Nutrition: Church & Dwight Challenges Ashwagandha Claims

NAD review of Goli claims, looking at weight loss, physical performance, sexual function and sales claims, recommended it modify advertising to avoid conveying implied product efficacy claims for Ashwagandha Gummies and modify or discontinue qualified physical performance claim about ingredient KSM-66.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts